BioSpace News Archive

Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster highlighting new preclinical data on NKTR-255 at the 65th American Society of Hematology (ASH) Annual Meeting.

Johnson & Johnson announced new patient-reported outcomes from the Phase 3 CARTITUDE-4 study of CARVYKTI® demonstrated clinically meaningful improvements in health-related quality of life and meaningful reductions in disease-specific symptoms according to multiple PRO measures in the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy.

Vertex Pharmaceuticals Incorporated announced two oral presentations at the American Society of Hematology Annual Meeting and Exposition from the global pivotal trials of CASGEVY™.

Disc Medicine, Inc. presented updated results from the phase 2 open-label BEACON study of bitopertin, an orally administered glycine transporter 1 inhibitor, in patients with erythropoietic protoporphyria as an oral presentation at the 65th ASH Annual Meeting.

Bristol Myers Squibb and 2seventy bio, Inc. announced results from the preplanned final progression-free survival analysis of KarMMa-3, the pivotal Phase 3, open-label, global, randomized controlled study evaluating Abecma compared with standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, reported data from the Phase 1 study of HPN217 in patients with RRMM in an oral presentation at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego.

Kite, a Gilead Company, announced the results of four new analyses supporting the use of Tecartus® in relapsed/refractory mantle cell lymphoma and relapsed/refractory adult B-cell precursor acute lymphoblastic leukemia.

Bristol Myers Squibb announced updated results from three key programs within its broad multiple myeloma research pipeline, highlighting its diverse targets and molecular approaches to address unique patient needs within the disease.

Cimeio Therapeutics, the leading biotechnology company in the field of epitope shielding, presented data for its CD45 and CD33 programs during this weekend’s American Society of Hematology meeting in San Diego.

Kite, a Gilead Company, announced data from follow-up analyses of three studies of Yescarta® that demonstrate the long-term survival potential for patients living with several sub-types of relapsed or refractory non-Hodgkin lymphoma, which were presented at the 65th American Society of Hematology Annual Meeting & Exposition.